TORINO, Italy--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables revenue..

意大利都灵--（商业新闻短讯）--布鲁克公司（Nasdaq:BRKR）很高兴宣布以8.7亿欧元现金收购ELITechGroup（“ELITech”），不包括ELITech临床化学业务。ELITech是分子诊断（MDx）、生物医学系统/专业IVD和微生物学系统和分析的差异化、快速增长和盈利提供商，2023财年收入约1.5亿欧元，消耗品收入超过80%。

“We are very pleased to welcome ELITech to Bruker,” said Frank H. Laukien, Bruker’s President and CEO. “The ELITech molecular diagnostics sample-to-answer platforms for viral infection and other esoteric MDx assays complement our MALDI Biotyper® platform for bacterial and fungal identification. The combined offerings establish Bruker as an innovative and growing infectious disease specialist in the in-vitro diagnostics (IVD) market.”.

布鲁克总裁兼首席执行官弗兰克·劳金（FrankH.Laukien）表示：“我们非常高兴地欢迎ELITech加入布鲁克。”。“ELITech molecular diagnostics sample to answer platform for viral infection and other Esteric MDx Assay补充了我们的MALDI Biotyper®细菌和真菌鉴定平台。这些组合产品使布鲁克成为体外诊断（IVD）市场上创新且不断成长的传染病专家。”

“Bruker’s portfolio is a perfect strategic fit for ELITech’s products,” said Dr. Christoph Gauer, the CEO of ELITech. “Both companies share a passion for innovation, and both have a history of bringing disruptive products to the IVD market. The ELITech team is very much looking forward to becoming part of the Bruker family.”.

ELITech首席执行官克里斯托夫·高尔博士表示：“布鲁克的投资组合非常适合ELITech的产品。”。“两家公司都有创新的热情，都有将颠覆性产品带入IVD市场的历史。ELITech团队非常期待成为布鲁克家族的一员。”

Going forward, ELITech will become the Bruker Molecular Diagnostics business within the Bruker Microbiology & Infection Diagnostics division of the Bruker CALID Group. For the remainder of 2024, Bruker expects the ELITech business to generate approximately $100 million of revenues within Bruker, with non-GAAP EBIT margins above 20%, and FY 2024 accretion of $0.08 - $0.10 to Bruker’s non-GAAP EPS, after acquisition financing costs..

展望未来，ELITech将成为Bruker CALID Group Bruker Microbiology&Infection Diagnostics部门内的Bruker Molecular Diagnostics业务。在2024年剩余时间内，布鲁克预计ELITech业务将在布鲁克内部产生约1亿美元的收入，非公认会计准则息税前利润率超过20%，并且在收购融资成本之后，2024财年布鲁克的非公认会计准则每股收益将增加0.08-0.10美元。

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

关于布鲁克公司-后基因组时代的领导者（纳斯达克：BRKR）

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels.

布鲁克使科学家和工程师能够取得突破性的后基因组发现，并开发改善人类生活质量的新应用。布鲁克的高性能科学仪器和高价值的分析和诊断解决方案使科学家能够在分子，细胞和微观水平上探索生命和材料。

In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI.

布鲁克与我们的客户密切合作，在后基因组生命科学分子和细胞生物学研究、应用和生物制药应用、显微镜和纳米分析、工业和清洁技术研究以及支持人工智能的下一代半导体计量学方面，实现创新、提高生产力和客户成功。

Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

布鲁克在临床前成像、临床表型研究、蛋白质组学和多组学、空间和单细胞生物学、功能结构和冷凝生物学以及临床微生物学和分子诊断领域提供差异化的高价值生命科学和诊断系统和解决方案。

For more information, please visit www.bruker.com..

欲了解更多信息，请访问www.bruker.com。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This communication contains “forward-looking statements” regarding Bruker’s acquisition of ELITechGroup. All statements, other than statements of historical facts, including statements concerning Bruker’s expectations regarding the ELITech business’ fiscal year 2024 financial outlook, including its revenues, non-GAAP EBIT margins and non-GAAP EPS accretion from the combined business; Bruker’s and NanoString’s plans, objectives, goals, beliefs, strategy and strategic objectives, future events, business conditions, results of operations, financial position, business outlook, business trends and other information, may be forward-looking statements.

该通信包含关于布鲁克收购ELITechGroup的“前瞻性声明”。除历史事实报表外的所有报表，包括关于布鲁克对ELITech业务2024财年财务前景的预期报表，包括其收入、非GAAP息税前利润率和合并业务产生的非GAAP EPS增量；布鲁克和纳斯特林的计划、目标、目标、信念、战略和战略目标、未来事件、商业状况、经营成果、财务状况、商业前景、商业趋势和其他信息可能是前瞻性陈述。

Forward-looking statements generally can be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” or “will” or the negatives of these terms or variations of them or similar terminology.

前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“预期”，“相信”，“沉思”，“继续”，“可能”，“估计”，“预期”，“目标”，“打算”，“可能”，“计划”，“潜力”，“预测”，“项目”，“寻求”，“应该”，“战略”，“目标”或“意志”，或这些术语的负面或其变化或类似术语。

Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

读者应注意，任何此类前瞻性陈述都不能保证未来的表现，并涉及风险和不确定性，并应注意不要过度依赖这些前瞻性陈述。由于存在许多风险和不确定性，实际结果可能与目前预期的结果存在重大差异。

Risks and uncertainties include, but are not limited to, Bruker’s ability to integrate the ELITech business and achieve the expected synergies; risks relating to the potential diversion of management’s attention from Bruker’s ongoing business operations; the risk that any announcements relating to the transaction could have adverse effects on the market price of Bruker’s common stock; and the risk that Bruker’s financial .

风险和不确定性包括但不限于布鲁克整合ELITech业务并实现预期协同效应的能力；与管理层可能将注意力从布鲁克正在进行的业务运营转移有关的风险；与交易有关的任何公告可能对布鲁克普通股的市场价格产生不利影响的风险；以及布鲁克的财务风险。